×
Vericel Operating Expenses 2010-2025 | VCEL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Vericel operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Vericel Operating Expenses 2010-2025 | VCEL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Vericel operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$218.1B
Amgen (AMGN)
$157.3B
Gilead Sciences (GILD)
$135.7B
Vertex Pharmaceuticals (VRTX)
$119.2B
Bristol Myers Squibb (BMY)
$94.5B
CSL (CSLLY)
$78.8B
GSK (GSK)
$77.4B
Regeneron Pharmaceuticals (REGN)
$59.2B
Alnylam Pharmaceuticals (ALNY)
$40.6B
Argenex SE (ARGX)
$34B
BioNTech SE (BNTX)
$26.6B
Royalty Pharma (RPRX)
$20.5B
Insmed (INSM)
$19.5B
Biogen (BIIB)
$18.7B
Illumina (ILMN)
$15.4B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.6B
Incyte (INCY)
$13.2B
Moderna (MRNA)
$12.2B
Exelixis (EXEL)
$12B
BioMarin Pharmaceutical (BMRN)
$10.9B
Ascendis Pharma (ASND)
$10.7B
QIAGEN (QGEN)
$10.5B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.4B
Bio-Techne Corp (TECH)
$8.1B
Roivant Sciences (ROIV)
$7.7B
Legend Biotech (LEGN)
$7.3B